BHC — Bausch Health Companies Inc.
Bausch Health Companies Inc., together with its subsidiaries, develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through five segments: Bausch + Lomb, Salix, International Rx, Ortho Dermatologics, and Diversified Products. The Bausch + Lomb segment offers products with a focus on the vision care, surgical, and consumer, surgical, and ophthalmic pharmaceuticals products. The Salix segment provides gastroenterology products in the United States. The International Rx segment offers Solta products, branded and generic pharmaceutical products, OTC products, and medical device products, and Bausch + Lomb products in Canada, Europe, Asia, Australia, Latin America, Africa, and the Middle East. The Ortho Dermatologics segment provides dermatological products in the United States; and Solta medical aesthetic devices internationally. The Diversified Products segment offers pharmaceutical products in the areas of neurology and other therapeutic classes, as well as generic and dentistry products in the United States. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.
Company profile
- Sector: Healthcare
- Industry: Drug Manufacturers - Specialty & Generic
- Country: CA
- Exchange: NYSE
- Employees: 20,700
- Website: https://www.bauschhealth.com
Latest SEC filings for BHC
- 10-Q — 2026-07-30
- 8-K — 2026-07-29
- 8-K — 2026-07-01
- 8-K — 2026-05-19
- 8-K — 2026-04-29
- ARS — 2026-04-08
- 8-K — 2026-03-02
- 10-K — 2026-02-19
- 8-K — 2026-02-18
- 8-K — 2026-01-23
Latest BHC news
- — Bausch + Lomb names Thomas Appio interim CEO, signals guidance hike (seekingalpha_market)
- — Six-Month Pilot Study Demonstrates Improved Guideline Adherence Following Implementation of Standardized Cirrhosis Clinical Pathway (prnewswire.com)
- — Bausch + Lomb and Bausch Health Announce Appointment of Thomas J. Appio as Interim Bausch + Lomb CEO, Expect to Raise Full-Year 2026 Guidance (businesswire.com)
- — Bausch Health to Announce Third Quarter 2026 Results on October 28, 2026 (prnewswire.com)
- — 4 Low-Beta Healthcare Stocks to Buy Amid Fears of Another Rate Hike (Zacks Investment Research)
- — 4 Low-Beta Healthcare Stocks to Buy Amid Fears of Another Rate Hike
- — Consumer Confidence Falls Amid Ongoing Geopolitical Tensions: 4 Picks (Zacks Investment Research)
- — Consumer Confidence Falls Amid Ongoing Geopolitical Tensions: 4 Picks (zacks.com)
- — Head-To-Head Contrast: Bristol Myers Squibb (NYSE:BMY) vs. Bausch Health Cos (NYSE:BHC)
- — Acne Vulgaris Market Set for Significant Growth During the Forecast Period (2026–2036), Amid Rising Disease Burden and Therapeutic Advances | DelveInsight (GlobeNewswire Inc.)
Educational tool only — not investment advice.